Interaction of misonidazole and WR-2721--II. Modification of tumour radiosensitization.
Two types of mouse tumour have been used to study the radiomodifying actions of Misonidazole (MISO) and WR-2721 when used alone and in combination with each other. Single dose studies were performed in both of the tumours and fractionated studies were performed on the anaplastic carcinoma, CA MT. Radioprotection with WR-2721 was seen in both tumours, being most marked at low X-ray doses. The protection was more obvious and the sensitization by MISO less in the fractionated experiment. The combination of MISO and WR-2721 gave an intermediate response compared with either drug used alone, resulting in some sensitization with single doses and an overall protection with repeated small doses. An interactive toxicity of the 2 drugs was also observed, suggesting an additive effect when assessed in terms of lethality. These studies indicate that the effects of both MISO and WR-2721 are dependent upon the oxygen status of the cells in the tumour, and that MISO can act in an oxygen-mimetic manner to modify the radioprotection observed with WR-2721.
D004999:Amifostine / Q000627:therapeutic use*; D000818:Animals; D002455:Cell Division; D002470:Cell Survival; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005354:Fibrosarcoma / Q000473:pathology / Q000532:radiotherapy; D051379:Mice; D008920:Misonidazole / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D011836:Radiation Tolerance; D012513:Sarcoma, Experimental / Q000473:pathology / Q000532:radiotherapy
D009593:Nitroimidazoles; D009946:Organothiophosphorus Compounds; D008920:Misonidazole; D004999:Amifostine